Skip to content
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Endocrinology · Secondary Hypopituitarism

Can a Large Prolactinoma Affect Your Other Hormones?

At a Glance

A large prolactinoma can compress healthy pituitary tissue, causing a drop in other essential hormones like cortisol, thyroid, and sex hormones. This mass effect can lead to fatigue, dizziness, and weight changes. Shrinking the tumor with medication or surgery can often reverse these deficiencies.

Yes, a large prolactinoma can absolutely affect other vital hormones in your body, such as your thyroid and cortisol levels. When a prolactinoma grows large enough to be classified as a macroprolactinoma (a tumor 10 millimeters, or 1 cm, or larger) or a giant prolactinoma (typically over 40 millimeters, or 4 cm), it takes up significant space within the tight, bony enclosure where the pituitary gland sits. This physical crowding can press against the healthy, normal tissue of your pituitary gland, preventing it from producing other crucial hormones [1]. This cascading failure of other endocrine systems is known as secondary hypopituitarism or secondary pituitary deficiency [2]. Treating a large prolactinoma requires monitoring not just your prolactin levels, but ensuring your entire endocrine system remains balanced.

How Large Tumors Cause the “Mass Effect”

Your pituitary gland is the “master gland” that controls several different hormone systems throughout your body. Because the gland sits in a very small pocket of bone at the base of your skull, there isn’t much room for a tumor to grow without pressing on surrounding structures.

When a macroprolactinoma expands, it physically compresses the healthy pituitary tissue [1][3]. It can also pinch the delicate pituitary stalk, the connection between your brain’s hypothalamus and the pituitary gland, which disrupts the normal signaling needed to release hormones [1]. This mechanical pressure is called the mass effect. If the pressure becomes too great, the normal cells stop functioning properly, leading to a drop in the production of other essential hormones [2][4]. Additionally, upward expansion can press on the optic nerves (the optic chiasm), which may cause visual disturbances such as loss of peripheral vision [5][6]. In the most severe cases of giant prolactinomas, a person might experience panhypopituitarism, which means there is a deficiency in multiple or all of the pituitary hormones [3][7].

Which Hormones Are at Risk?

When a macroprolactinoma compresses healthy tissue, several key hormone systems can be affected:

  • Cortisol (Secondary Adrenal Insufficiency): The pituitary gland normally releases ACTH (adrenocorticotropic hormone), which tells your adrenal glands to produce cortisol—your body’s primary stress hormone [8]. If the tumor blocks ACTH production, cortisol levels drop [8]. Unlike primary adrenal insufficiency (Addison’s disease), this secondary type usually does not cause skin darkening or severe changes in your body’s salt levels [9][10].
  • Thyroid Hormone (Central Hypothyroidism): Your pituitary produces TSH (thyroid-stimulating hormone), which signals your thyroid gland to make thyroid hormones. A large tumor can reduce TSH, leading to an underactive thyroid [11][12]. Crucially, doctors must check for and treat adrenal insufficiency before starting you on thyroid medication, as taking thyroid hormone with untreated low cortisol can trigger a life-threatening adrenal crisis [11][13].
  • Sex Hormones (Secondary Hypogonadism): High prolactin levels directly suppress the signals that trigger the release of sex hormones (LH and FSH), but the physical compression from a large tumor also damages the cells responsible for these hormones [14][15]. This leads to low testosterone in men and low estrogen in women [16].
  • Growth Hormone: The cells that produce growth hormone are also frequently impacted by the mass effect of large tumors, leading to growth hormone deficiency [7][3].

Symptoms to Watch For

Because the loss of these hormones can happen slowly as the tumor grows, the symptoms are often subtle, insidious, and easily mistaken for general illness or stress [8][17]. You should be on the lookout for:

  • Adrenal Insufficiency: Severe and unexplained fatigue, loss of appetite, persistent nausea, general malaise, dizziness when standing up (orthostatic hypotension), and unintended weight loss [8][18]. In severe cases, you might experience fainting (syncope) [19].
  • Hypothyroidism: Feeling unusually cold, sluggishness, dry skin, thinning hair, and weight gain [11].
  • Hypogonadism: In women, this causes periods to become irregular or stop completely. In men, it leads to decreased libido (sex drive) and erectile dysfunction [20][15].
  • Growth Hormone Deficiency: Adult symptoms can be vague, including changes in body composition (increased fat, decreased muscle), fatigue, and a reduced overall sense of well-being or quality of life [7].

Safety Warning: If you experience severe signs of an adrenal crisis—such as intractable vomiting, extreme weakness, confusion, or sudden fainting—seek emergency medical care immediately. This is a life-threatening condition that requires prompt treatment with corticosteroids [8][18].

The Need for Comprehensive Monitoring

Because the health of your whole body depends on these hormones, treating a macroprolactinoma involves more than just bringing your prolactin levels down.

When you are diagnosed with a large prolactinoma, your doctor should order a comprehensive hormone panel [16][2]. This baseline bloodwork shouldn’t just look at prolactin, but also check your morning cortisol, TSH, free T4 (thyroid hormone), IGF-1 (a marker for growth hormone), and your sex hormones (FSH, LH, and testosterone or estradiol) [16].

It is important that this bloodwork be drawn early in the morning (e.g., around 8:00 AM). Cortisol and testosterone naturally fluctuate throughout the day and peak in the early morning, so an afternoon test might yield inaccurate or misleading results [16].

Long-term, periodic monitoring (often every 6 to 12 months, depending on your treatment plan) of these hormone levels and the size of your tumor on an MRI is critical to ensure that any developing deficiencies are caught and treated early [21][22].

Hormone Recovery

The encouraging news is that pituitary hormone deficiencies caused by compression are not always permanent. When a macroprolactinoma shrinks—either through the use of dopamine agonist medications (like cabergoline) or through surgical decompression—the pressure on the healthy pituitary tissue is relieved [3][23].

Following treatment, patients often see partial or complete recovery of their other pituitary hormones [3]. For example, about two-thirds of men with macroprolactinomas who experience hypogonadism recover normal sex hormone function within 24 months of starting dopamine agonist therapy [24]. Recovery depends on how much pre-existing damage occurred to the gland, making early diagnosis and treatment essential [23][25].

Common questions in this guide

Can a large prolactinoma cause low cortisol or low thyroid levels?
Yes. A large tumor can press on the healthy parts of your pituitary gland, blocking the signals that tell your adrenal and thyroid glands to produce hormones. This can lead to secondary adrenal insufficiency and central hypothyroidism.
What are the symptoms of a prolactinoma pressing on the pituitary gland?
Symptoms depend on which hormones are reduced, but can include severe fatigue, dizziness when standing up, feeling unusually cold, irregular periods, and decreased sex drive. If the tumor presses upward, you might also experience a loss of peripheral vision.
Will my other hormones return to normal if my prolactinoma shrinks?
When medications or surgery reduce the size of the tumor, the physical pressure on your healthy pituitary tissue is relieved. Because of this, many patients see a partial or complete recovery of their other hormone levels over time.
Why do I need a morning blood test if I have a macroprolactinoma?
Your doctor needs to check a comprehensive panel to ensure your entire endocrine system is balanced, not just prolactin. Hormones like cortisol and testosterone naturally peak in the early morning, so an 8:00 AM blood draw ensures the most accurate results.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given the size of my prolactinoma (in centimeters), which of my other pituitary hormones should we monitor most closely?
  2. 2.Do I need to check my morning cortisol and thyroid levels before starting any new treatments?
  3. 3.If my tumor shrinks with medication, is it possible for my other hormone levels to return to normal?
  4. 4.What specific symptoms, like dizziness or persistent nausea, should prompt me to go to the ER or contact you immediately?
  5. 5.How often will we repeat the comprehensive hormone panel and MRI to monitor my progress?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Myxedema Coma Associated with Macroprolactinoma: Case Report and Review of the Literature.

    Omoniyi EJ, Robbins RJ

    Case reports in endocrinology 2022; (2022()):1591616 doi:10.1155/2022/1591616.

    PMID: 35528636
  2. 2

    An uncommon cause for hip pain and limping.

    Shetty S, Sathyakumar S, Kapoor N, Paul TV

    Journal of family medicine and primary care 2015; (4(3)):468-9 doi:10.4103/2249-4863.161357.

    PMID: 26288794
  3. 3

    A case of giant prolactinoma and pituitary hemorrhage with the late recovery of pituitary function: A case report.

    Menon LP, Edem D

    SAGE open medical case reports 2023; (11()):2050313X231190672 doi:10.1177/2050313X231190672.

    PMID: 37533485
  4. 4

    Rare case of primary granulomatous hypophysitis mimicking pituitary macroadenoma: A diagnostic challenge.

    Sharma A, Mathew B, Gupta D, Gahlot GPS

    Indian journal of pathology & microbiology 2026; (69(1)):156-158 doi:10.4103/ijpm.ijpm_660_25.

    PMID: 41553166
  5. 5

    Pituitary Macroadenoma Presenting With Monocular Temporal Hemianopia.

    Gupta A, Deshmukh M, Palexas G

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2021; (41(2)):e267-e268 doi:10.1097/WNO.0000000000001119.

    PMID: 33136669
  6. 6

    Clinical characteristics and ophthalmologic findings of pituitary adenoma in Korean patients.

    Kim TG, Jin KH, Kang J

    International ophthalmology 2019; (39(1)):21-31 doi:10.1007/s10792-017-0778-x.

    PMID: 29274021
  7. 7

    Hypopituitarism patterns among adult males with prolactinomas.

    Peng J, Qiu M, Qi S, et al.

    Clinical neurology and neurosurgery 2016; (144()):112-8.

    PMID: 27038873
  8. 8

    A case of small-cell lung cancer with adrenocorticotropic hormone deficiency induced by nivolumab.

    Zhu Y, Wu HH, Wang W

    OncoTargets and therapy 2019; (12()):2181-2186 doi:10.2147/OTT.S194094.

    PMID: 30988622
  9. 9

    A rare cause of chronic hyponatremia in an infant: Answers.

    Mutlu GY, Taşdemir M, Kızılkan NU, et al.

    Pediatric nephrology (Berlin, Germany) 2020; (35(2)):243-245 doi:10.1007/s00467-019-04337-0.

    PMID: 31428928
  10. 10

    SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients.

    Arlt W,

    Endocrine connections 2016; (5(5)):G1-G3 doi:10.1530/EC-16-0054.

    PMID: 27935813
  11. 11

    Subclinical hypothyroidism or central hypothyroidism-The danger of thyroid function misinterpretation.

    Anyiam O, Cheung B, Al-Sabbagh S

    Clinical case reports 2018; (6(10)):1953-1957 doi:10.1002/ccr3.1694.

    PMID: 30349705
  12. 12

    Nivolumab induced hypophysitis in a patient with recurrent non-small cell lung cancer.

    Kajal S, Gupta P, Ahmed A, Gupta A

    Drug discoveries & therapeutics 2021; (15(4)):218-221 doi:10.5582/ddt.2021.01006.

    PMID: 34456195
  13. 13

    Hypothyroidism With ACTH Deficiency During Pembrolizumab Therapy for Lung Cancer: Case Report and Literature Review.

    Hashinokuchi A, Haro A, Minagawa R, et al.

    Cancer diagnosis & prognosis 2023; (3(4)):498-503 doi:10.21873/cdp.10246.

    PMID: 37405219
  14. 14

    Foster Kennedy syndrome secondary to a giant prolactinoma with a remarkable response to cabergoline.

    Kanj U, Lee SS, Wattegama M, et al.

    Endocrinology, diabetes & metabolism case reports 2022; (2022()).

    PMID: 36017805
  15. 15

    Arrested Puberty in a Young Adult With a Macroprolactinoma: Case Report and Literature Review.

    M S, M O, P F, M P

    Case reports in endocrinology 2025; (2025()):5388529 doi:10.1155/crie/5388529.

    PMID: 39949381
  16. 16

    Successful diagnosis and monitoring of giant prolactinomas: the role of sample dilutions.

    Schlegel A, Straseski JA

    Laboratory medicine 2025; (56(6)):786-789 doi:10.1093/labmed/lmaf021.

    PMID: 40493766
  17. 17

    Real-World Incidence of Immune-Related Adverse Events Associated with Nivolumab Plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma: A Retrospective Observational Study.

    Washino S, Takeshita H, Inoue M, et al.

    Journal of clinical medicine 2021; (10(20)) doi:10.3390/jcm10204767.

    PMID: 34682890
  18. 18

    A case of isolated sinus bradycardia as an unusual presentation of adrenal insufficiency.

    Reyes JVM, Majeed H, Song D, et al.

    Annals of medicine and surgery (2012) 2021; (69()):102727 doi:10.1016/j.amsu.2021.102727.

    PMID: 34457259
  19. 19

    Slowly Progressive Secondary Adrenal Insufficiency Due to Pembrolizumab Administration in a Patient With a History of Pituitary Neuroendocrine Tumor.

    Ueda H, Fujita Y, Mukai K, et al.

    Cureus 2025; (17(3)):e81495 doi:10.7759/cureus.81495.

    PMID: 40308384
  20. 20

    A rare case of a giant prolactinoma with atypical histological features: 5 years of follow-up.

    Vasilakis IA, Paltoglou G, Gavra M, Charmandari E

    Hormones (Athens, Greece) 2022; (21(2)):323-327 doi:10.1007/s42000-022-00350-5.

    PMID: 35143036
  21. 21

    Natural history of pituitary carcinoma with metastasis to the cervical spine: illustrative case.

    Gamboa NT, Wilkerson C, Kundu B, et al.

    Journal of neurosurgery. Case lessons 2023; (5(3)).

    PMID: 36647250
  22. 22

    Prolactinoma: Navigating the Dual Challenge of Side Effects and Treatment Strategies - A Comprehensive Review.

    Yogeeta F, Rauf SA, Devi M, et al.

    Annals of medicine and surgery (2012) 2024; (86(8)):4613-4623 doi:10.1097/MS9.0000000000002308.

    PMID: 39118737
  23. 23

    Recovery of hypopituitarism in macroprolactinomas: a comparison of medical vs. surgical treatment. Results from a European multicenter study.

    Detomas M, Altieri B, Nasi-Kordhishti I, et al.

    Journal of endocrinological investigation 2025; (48(6)):1363-1370 doi:10.1007/s40618-025-02559-8.

    PMID: 40035956
  24. 24

    Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists.

    Al Dahmani KM, Almalki MH, Ekhzaimy A, et al.

    Pituitary 2022; (25(4)):658-666 doi:10.1007/s11102-022-01242-y.

    PMID: 35793046
  25. 25

    The Role of Dopamine Agonists in Pituitary Adenomas.

    Giraldi EA, Ioachimescu AG

    Endocrinology and metabolism clinics of North America 2020; (49(3)):453-474 doi:10.1016/j.ecl.2020.05.006.

    PMID: 32741482

This page provides educational information on how prolactinomas can impact other hormones. It is not medical advice. Always consult your endocrinologist regarding your hormone levels, symptoms, and treatment plan.

Get notified when new evidence is published on Prolactinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.